Massive pulmonary embolism during pregnancy treated with
streptokinase and complicated by massive haemorrhage --a case report].
4)
Streptokinase has been shown to be effective in salvaging clotted blood and bone marrow specimens for flow cytometric immunophenotyping and has been successfully used to treat clotted samples before proceeding with cellular immune assays.
The result of total proteolytic activity in terms of specific activity in latex of Synadenium grantii compared with Papain and
streptokinase tabulated in Table 2
Randomised controlled trial of intrapleural
streptokinase in community acquired pleural infection.
Assay of fibrinolytic activity: The original fibrin plate method of Astrup and Mullertz (29) with slight modification was used for measuring the fibrinolytic activity of the test preparation along with
streptokinase.
Acute renal failure, hypertension and skin necrosis in a patient with
streptokinase therapy.
While fibrinoloytic agents such as
streptokinase break up only the fibrin element of the clot, ANGIOMAX targets thrombin.
The defendant physician as well as the hospital, which was also joined as a defendant, maintained that the patient did not suffer from cardiogenic shock and that the conditions that ultimately required the amputation of his extremities resulted from "an unexpected, rare, and severe sensitivity reaction to
streptokinase that the patient received in the hospital's emergency center.
Similarly, in a cost-effective analysis of thrombolytic therapy with tissue plasminogen activator (t-PA) compared to
streptokinase, the authors conclude, "The cost-effectiveness of treatment with accelerated t-PA rather than
streptokinase compares favorably with that of other therapies whose added medical benefit for dollars spent is judged by society to be worthwhile.
Q MY husband had a heart attack at the New Year and was given
Streptokinase.
An Oxford-based study of different anti-clotting drugs showed that aspirin cut death rates in heart attack cases by 20 per cent and by 40 per cent when given with the clot-buster
streptokinase.
This study, named VITAL, slated for completion in late 1998, is designed to determine the optimal dose of Vasoflux when used in conjunction with
streptokinase for patients with acute infarction (AMI or heart attack).
